

DISCUSSION

Alan Menius

GSK

Building a pharmacovigilance system

Tuning the process:

Data

Health Outcome of Interest (HOI)

Common Data Model (CDM)

Research Design

Analysis method(s)

Analysis parameters

Validation/QA

Communicating results

OMOP as a building block for future research

- ▣ Patient Centered Predictive Models
 - Find subpopulations of patients with increase risk

- ▣ The system and learnings can be applied outside pharmacovigilance